Organic Vaccines is a biotech in the final stage of development of a patented, personalized, DNA vaccine that uses an individual's own cells. This new flu vaccine addresses the pain points in an underserved flu market. With a renowned Scientific Advisory Board, including a Nobel Prize recipient and partners such as Sloan Kettering in NY and Inserm in Pariswe are doing the first-in-man this year, and a Phase III clinical trial within 12 months. The company and its patent portfolio will be sold to a pharma looking for new IP and who will have the capacity to bring the service to market.